OTTAWA, March 24, 2017 /CNW/ - Tuberculosis (TB) is preventable and curable, yet it remains one of the most common infectiousdiseases worldwide. In Canada, rates of TB are low; however, there is greater incidence among Canadian Indigenous people and among foreign-born individuals from countries where TB is common.
Today, the Honourable
The first phase of the study is currently underway in Iqaluit in partnership with the Ottawa Hospital Research Institute, the Government of Nunavut, Nunavut Tunngavik Inc. and Inuit Tapiriit Kanatami. The second phase of the study — led by the Ottawa Hospital Research Institute in partnership with Ottawa Public Health and the Children's Hospital of Eastern Ontario — will replicate the northern study with communities in Ottawa.
Latent TB is a condition in which TB bacteria are alive but inactive in the body. During this time, people have no symptoms, do not feel sick, and cannot spread TB to others. The standard treatment of latent TB infection consists of daily treatment for nine months. In recent years, shorter treatment regimens have been developed with the aim of increasing rates of treatment acceptance, compliance and completion. The shortest and most recently developed treatment regimen is 3HP, which is taken once weekly for 12 weeks. The TB 3HP study will contribute to the knowledge base that currently suggests that 3HP is a promising alternative to existing treatments for latent TB.
"The Government of Canada is pleased to support this important study, which will provide new knowledge about the feasibility, cost-effectiveness and acceptance of 3HP as a treatment option for latent TB. Through collaborative community-based initiatives such as the Taima TB 3HP study, we will continue to identify real solutions to address this curable disease."
The Honourable Jane Philpott, P.C., M.P.Minister of Health
"Treating latent TB infection in order keep people from developing active TB disease has always been challenging because the current therapy takes so long. I am very pleased that we will be able to offer a safe and effective treatment that takes a fraction of the time to complete."
Dr. Gonzalo Alvarez MD, MPH, FRCPCProgram Director, Taima TBScientist and Respirologist, The Ottawa Hospital Associate Professor, University of OttawaRespirology & Tuberculosis Consultant, Nunavut Department of Health
Associated Links TuberculosisTuberculosis Prevention and Control in Canada: A Federal Framework for ActionTaima TBTaima 3HP TB study
SOURCE Public Health Agency of Canada
Subscribe to our Free Newsletters!
Acute coronary syndrome (ACS) is a sudden, acute life-threatening condition caused by a dramatic ...
Sclerotherapy is a procedure used to treat spider veins, varicose veins and hemorrhoids by directly ...
HELLP syndrome is a rare but serious complication that affects pregnant women. If detected on time, ...View All